Health care practitioners have debated on the most appropriate course of treatment for individuals with chronic kidney disease (CKD) and other comorbidities, including diabetes and bone mineral disorder, as these individuals are often at a higher risk of adverse events and mortality. In recent years, professional organizations have published clinical practice guidelines on the management of CKD and other comorbidities.
In your opinion, do you believe these guidelines sufficiently address these controversies in management?